(Q43937942)

English

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

scientific article published in March 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

based on heuristic

inferred from title

author name string

Victoria J Sinibaldi

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Michael A Carducci

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sandra Moore-Cooper

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Menachem Laufer

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Marianna Zahurak

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Mario A Eisenberger

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 March 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1457-1465

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Nuclear protein matrix as a target for estramustine-induced cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by Roswell Park Memorial Institute

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Clinical radiosensitization: why it does and does not work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10350

21 January 2018

Identifiers

10.1002/CNCR.10350

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43937942&oldid=2104516700"